230 related articles for article (PubMed ID: 10184096)
1. Biological products; blood specificity designators; technical amendments--FDA. Final rule; technical amendments.
Fed Regist; 1994 May; 59(87):23636-7. PubMed ID: 10184096
[TBL] [Abstract][Full Text] [Related]
2. Revision to requirements for licensed Anti-Human Globulin and Blood Grouping Reagents. Food and Drug Administration, HHS. Direct final rule.
Fed Regist; 2000 Dec; 65(239):77497-9. PubMed ID: 11503726
[TBL] [Abstract][Full Text] [Related]
3. Revisions to the requirements applicable to blood, blood components, and source plasma. Final rule.
Food and Drug Administration, HHS
Fed Regist; 2001 Aug; 66(151):40886-90. PubMed ID: 11732557
[TBL] [Abstract][Full Text] [Related]
4. Revisions to the requirements applicable to blood, blood components and source plasma. Direct final rule.
Food and Drug Administration, HHS
Fed Regist; 2007 Aug; 72(158):45883-88. PubMed ID: 17847577
[TBL] [Abstract][Full Text] [Related]
5. Revisions to the requirements applicable to blood, blood components, and source plasma; confirmation in part and technical amendment. Food and Drug Administration, HHS. Direct final rule; confirmation in part and technical amendment.
Fed Regist; 2001 Jan; 66(7):1834-7. PubMed ID: 11503754
[TBL] [Abstract][Full Text] [Related]
6. Revisions to the requirements applicable to blood, blood components and source plasma; confirmation of effective date and technical amendment. Direct final rule; confirmation of effective date and technical amendment.
Food and Drug Administration, HHS
Fed Regist; 2008 Feb; 73(27):7463-4. PubMed ID: 18389917
[TBL] [Abstract][Full Text] [Related]
7. Distribution of blood derivatives by registered blood establishments that qualify as health care entities; Prescription Drug Marketing Act of 1987; Prescription Drug Amendments of 1992; delay of applicability date. Final rule; delay of applicability date.
Food and Drug Administration, HHS
Fed Regist; 2006 Nov; 71(218):66108-9. PubMed ID: 17099971
[TBL] [Abstract][Full Text] [Related]
8. Revisions to the requirements applicable to blood, blood components, and source plasma. Department of Health and Human Services (HHS), Public Health Service (PHS), Food and Drug Administration (FDA). Direct final rule.
Fed Regist; 1999 Aug; 64(160):45366-74. PubMed ID: 10558597
[TBL] [Abstract][Full Text] [Related]
9. Internal analgesic, antipyretic, and antirheumatic drug products for over-the-counter human use; final rule for professional labeling of aspirin, buffered aspirin, and aspirin in combination with antacid drug products; technical amendments. Department of Health and Human Services (HHS), Public Health Service (PHS), Food and Drug Administration (FDA). Final rule; technical amendments.
Fed Regist; 1999 Sep; 64(177):49652-5. PubMed ID: 10915461
[TBL] [Abstract][Full Text] [Related]
10. Biological products: reporting of biological product deviations in manufacturing. Food and Drug Administration, HHS. Final rule.
Fed Regist; 2000 Nov; 65(216):66621-35. PubMed ID: 11503696
[TBL] [Abstract][Full Text] [Related]
11. Biologics products; establishment registration and product listing for manufacturers of human blood and blood products; amendment to exempt certain transfusion services from registration--FDA. Final rule.
Fed Regist; 1984 Aug; 49(171):34448-51. PubMed ID: 10299643
[TBL] [Abstract][Full Text] [Related]
12. Delegations of authority and organization; Center for Biologics Evaluation and Research, Center for Devices and Radiological Health, and Center for Drug Evaluation and Research--FDA. Final rule.
Fed Regist; 1991 Nov; 56(225):58758-9. PubMed ID: 10115699
[TBL] [Abstract][Full Text] [Related]
13. Biological technical amendment--FDA. Final rule; technical amendment.
Fed Regist; 1992 Apr; 57(64):11263. PubMed ID: 10118456
[TBL] [Abstract][Full Text] [Related]
14. Medical devices; hearing aids; technical data amendments. Direct final rule.
Food and Drug Administration, HHS
Fed Regist; 2008 Jun; 73(106):31358-60. PubMed ID: 18677822
[TBL] [Abstract][Full Text] [Related]
15. Regulations requiring manufacturers to assess the safety and effectiveness of new drugs and biological products in pediatric patients--FDA. Final rule.
Fed Regist; 1998 Dec; 63(231):66631-72. PubMed ID: 10338880
[TBL] [Abstract][Full Text] [Related]
16. Requirements for testing human blood donors for evidence of infection due to communicable disease agents. Final rule.
Food and Drug Administration, HHS
Fed Regist; 2001 Jun; 66(112):31146-65. PubMed ID: 11725786
[TBL] [Abstract][Full Text] [Related]
17. Revision of requirements applicable to albumin (human), plasma protein fraction (human), and immune globulin (human). Food and Drug Administration, HHS. Direct final rule.
Fed Regist; 1999 May; 64(93):26282-7. PubMed ID: 10558530
[TBL] [Abstract][Full Text] [Related]
18. Orthopedic devices: classification and reclassification of pedicle screw spinal systems; technical amendment. Final rule; technical amendment.
Food and Drug Administration, HHS
Fed Regist; 2001 May; 66(99):28051-3. PubMed ID: 11712575
[TBL] [Abstract][Full Text] [Related]
19. Exemption of certain transfusion services and clinical laboratories from registration: Food and Drug Administration. Final rule.
Fed Regist; 1980 Dec; 45(251 Pt 1):85727-30. PubMed ID: 10298064
[TBL] [Abstract][Full Text] [Related]
20. Expedited safety reporting requirements for human drug and biological products; correction--FDA. Final rule; correction.
Fed Regist; 1998 Mar; 63(58):14611-2. PubMed ID: 10177754
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
